Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2019 Earnings Conference Call - Final Transcript

May 08, 2019 • 04:30 pm ET


Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good day, ladies and gentlemen, and welcome to the Sarepta Therapeutics' First Quarter 2019 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later we'll conduct a question-answer session and instructions will be given at that time. (Operator Instructions).

As a reminder today's program is being recorded. I now like to introduce your host for today's program, Ian Estepan, Senior Vice President, Chief of Staff and Corporate Affairs. Please go ahead.

Ian M. Estepan

Thank you, Valorie, and thank you all for joining today's call. Earlier today, we released our financial results for the first quarter 2019. The press release is available on our website at, and our 10-Q was filed with the SEC earlier this afternoon.

Joining us on the call today are Doug Ingram, Sandy Mahatme, Bo Cumbo, Gilmore O'Neill and Louise Rodino-Klapac. After our formal remarks, we'll open the call up for Q&A.

I'd like to note that during this call, we will be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties, any of which are beyond Sarepta's control.

Actual results could materially differ from these forward-looking statements and any of such risks can materially and adversely affect the business, the results of operations and trading prices for Sarepta's common stock. For a detailed description of applicable risks and uncertainty, we encourage you to review the Company's most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission as well as the Company's other SEC filings.

The Company does not undertake any obligation to publicly update its forward-looking statements, including any financial projections provided today based on subsequent events or circumstances.

With that, let me turn the call over to Doug Ingram, our CEO who will provide an overview of our recent progress. Doug?

Douglas S. Ingram

Thank you, Ian. Good afternoon, and thank you all for joining Sarepta Therapeutics on its 2019 first quarter results and corporate update conference call. In 2017 and 2018, we defined our ambition and then gathered the tools necessary to achieve that ambition.

Our vision was audacious, but also very specific. As a fully integrated commercial stage biotechnology Company with a multi platform approach, we intend on being among the world leaders in precision genetic medicine. For our RNA platform, that means advancing our PMO technology to treat greater segments of the patient population with our exon skipping therapies, advancing our next generation PPMO technology, which if successful, could be a significantly more efficient version of our PMO technology and bringing our R&A platform and expertise to new therapeutic diseases that could benefit from our share of blockchain technology.

And for our gene therapy platform it means building out our durable gene therapy model by focusing on few interim related exercises. One, advancing our multi-therapeutic gene therapy engine already producing the broadest late stage gene therapy pipeline in biotech.

And two, advancing our hybrid manufacturing model with the goal